

Abstract

The present invention relates to a formulation optimized for a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor. Specifically, the present invention relates to an aqueous pharmaceutical formulation comprising a fusion protein dimer comprising an extracellular domain of an alpha subunit of an IgE Fc receptor, histidine, proline, methionine, and poloxamer 188, wherein the pH of the formulation is from 6.0 to 7.0. The fusion protein present in the formulation according to the present invention is included at a high concentration, has improved stability, may be conveniently administered by subcutaneous injection, and has excellent IgE binding ability compared to a conventional therapeutic agent comprising an anti-IgE antibody. Thus, it can be usefully utilized as an injection for the treatment of allergic diseases mediated by IgE.